Please login to the form below

Not currently logged in
Email:
Password:

Zocor

This page shows the latest Zocor news and features for those working in and with pharma, biotech and healthcare.

FDA panel rejects cardiovascular outcomes claim for Vytorin

FDA panel rejects cardiovascular outcomes claim for Vytorin

expire. Vytorin has been a somewhat controversial product for Merck since the publication of the ENHANCE trial, which compared the drug to simvastatin (Merck's now off-patent brand Zocor) alone

Latest news

More from news
Approximately 1 fully matching, plus 39 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics